<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04485663</url>
  </required_header>
  <id_info>
    <org_study_id>ALG-010133-101</org_study_id>
    <nct_id>NCT04485663</nct_id>
  </id_info>
  <brief_title>A Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects</brief_title>
  <official_title>A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-human Study of Subcutaneously Administered ALG-010133 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Ascending Doses (Part 1) and Multiple Ascending Doses in Healthy Volunteers (Part 2), and Multiple Doses in Subjects With Chronic Hepatitis B (Part 3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aligos Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aligos Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and
      Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 18, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>up to 15 days for Part 1</time_frame>
    <description>The number and severity of treatment emergent adverse events as assessed by DAIDS v2.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>up to 29 days for Part 2</time_frame>
    <description>The number and severity of treatment emergent adverse events as assessed by DAIDS v2.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>up to 162 days for Part 3</time_frame>
    <description>The number and severity of treatment emergent adverse events as assessed by DAIDS v2.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration [Cmax]</measure>
    <time_frame>Predose (0 hours) up to 162 Days (3864 hours)</time_frame>
    <description>Pharmacokinetic parameters of ALG-010133 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration time curve [AUC]</measure>
    <time_frame>Predose (0 hours) up to 162 Days (3864 hours)</time_frame>
    <description>Pharmacokinetic parameters of ALG-010133 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration [Tmax]</measure>
    <time_frame>Predose (0 hours) up to 162 Days (3864 hours)</time_frame>
    <description>Pharmacokinetic parameters of ALG-010133 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-time [t1/2]</measure>
    <time_frame>Predose (0 hours) up to 162 Days (3864 hours)</time_frame>
    <description>Pharmacokinetic parameters of ALG-010133 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Plasma Concentration [Cmin]</measure>
    <time_frame>Predose (0 hours) up to 162 Days (3864 hours)</time_frame>
    <description>Pharmacokinetic parameters of ALG-010133 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HBV DNA (reduction) from baseline through Day 78 in Multiple Dose HBV Infected Patients</measure>
    <time_frame>Screening, Day -1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">164</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>ALG-010133</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injections of ALG-010133 in HV or CHB subjects once every 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subcutaneous injections of placebo in HV or CHB subjects once every 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALG-010133</intervention_name>
    <description>Single or multiple doses of ALG-010133</description>
    <arm_group_label>ALG-010133</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single or multiple doses of Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Healthy Subjects:

          1. Male and Female between 18 and 55 years old

          2. Female subjects must have a negative serum pregnancy test at screening

          3. Subjects must be nonsmokers for at least 3 months prior to randomization

          4. BMI 18.0 to 32.0 kg/m^2

          5. Subjects must have a 12-lead ECG that meets protocol criteria

        Inclusion Criteria for CHB Subjects:

          1. Male and Female between 18 and 70 years old

          2. Female subjects must have a negative serum pregnancy test at screening

          3. BMI 18.0 to 35.0 kg/m^2

          4. HBeAg-negative chronic hepatitis B

          5. Subjects must have a 12-lead ECG that meets protocol criteria

        Exclusion Criteria for Healthy Subjects:

          1. Subjects with any current or previous illness that, in the opinion of the
             Investigator, might confound the results of the study or pose an additional risk in
             administering study drug to the subject or that could prevent, limit, or confound the
             protocol specified assessments or study results' interpretation

          2. Subjects with a past history of cardiac arrhythmias, risk factors for Torsade de
             Pointes syndrome (e.g., hypokalemia, family history of long QT Syndrome) or history or
             clinical evidence at screening of significant or unstable cardiac disease etc.

          3. Subjects with a history of clinically significant drug allergy

          4. Subject with current or history of clinically significant (as determined by the
             Investigator) skin disease requiring intermittent or chronic treatment

          5. Excessive use of alcohol defined as regular consumption of ≥14 units/week for women
             and ≥21 units/week for men

          6. Unwilling to abstain from alcohol use for 48 hours prior to start of dosing through
             end of study follow up

          7. Subjects with Hepatitis A, B, C, D, E or HIV-1/HIV-2 infection or acute infections
             such as SARS- CoV-2 infection

          8. Subjects with renal dysfunction (e.g., estimated creatinine clearance &lt;90 mL/min/1.73
             m^2 at screening, calculated by the Chronic Kidney Disease Epidemiology Collaboration
             [CKD-EPI] formula)

        Exclusion Criteria for CHB Subjects:

          1. Subjects with any current or previous illness that, in the opinion of the
             Investigator, might confound the results of the study or pose an additional risk in
             administering study drug to the subject or that could prevent, limit, or confound the
             protocol specified assessments or study results' interpretation

          2. Subjects with a past history of cardiac arrhythmias, risk factors for Torsade de
             Pointes syndrome (e.g., hypokalemia, family history of long QT Syndrome) or history or
             clinical evidence at screening of significant or unstable cardiac disease etc.

          3. Subjects with a history of clinically significant drug allergy

          4. Subject with current or history of clinically significant (as determined by the
             Investigator) skin disease requiring intermittent or chronic treatment

          5. Excessive use of alcohol defined as regular consumption of ≥14 units/week for women
             and ≥21 units/week for men

          6. Subjects with Hepatitis A, C, D, E or HIV-1/HIV-2 infection or acute infections such
             as SARS- CoV-2 infection

          7. Subjects with renal dysfunction (e.g., estimated creatinine clearance &lt;90 mL/min/1.73
             m^2 at screening, calculated by the Chronic Kidney Disease Epidemiology Collaboration
             [CKD-EPI] formula)

          8. Subject with any history or current evidence of hepatic decompensation such as:
             variceal bleeding, spontaneous bacterial peritonitis, ascites, hepatic encephalopathy,
             or active jaundice (within the last year)

          9. Subjects must have absence of signs of hepatocellular carcinoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ACS</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 9, 2020</study_first_submitted>
  <study_first_submitted_qc>July 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2020</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

